Abstract | AIMS: METHODS: RESULTS:
Lixisenatide had no effect on glucose metabolism. Lixisenatide preserved the retinal vasculature and neuroretinal function. The macro- and microglial activation was mitigated. Lixisenatide normalized some gene expression changes in diabetic animals to control levels. Ets2 was identified as a regulator of inflammatory genes. In C. elegans, lixisenatide showed the antioxidative property. CONCLUSIONS: Our data suggest that lixisenatide has a protective effect on the diabetic retina, most likely due to a combination of neuroprotective, anti-inflammatory and antioxidative effects of lixisenatide on the neurovascular unit.
|
Authors | Kuebra Oezer, Matthias Kolibabka, Johann Gassenhuber, Nadine Dietrich, Thomas Fleming, Andrea Schlotterer, Michael Morcos, Paulus Wohlfart, Hans-Peter Hammes |
Journal | Acta diabetologica
(Acta Diabetol)
Vol. 60
Issue 11
Pg. 1551-1565
(Nov 2023)
ISSN: 1432-5233 [Electronic] Germany |
PMID | 37423944
(Publication Type: Journal Article)
|
Copyright | © 2023. The Author(s). |
Chemical References |
- lixisenatide
- Hypoglycemic Agents
- Glucagon-Like Peptide-1 Receptor
- Antioxidants
- Glucose
|
Topics |
- Rats
- Animals
- Diabetic Retinopathy
(drug therapy, etiology, metabolism)
- Diabetes Mellitus, Type 2
(metabolism)
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Glucagon-Like Peptide-1 Receptor
(agonists)
- Caenorhabditis elegans
- Chromatography, Liquid
- Rats, Wistar
- Diabetes Mellitus, Experimental
(drug therapy, metabolism)
- Tandem Mass Spectrometry
- Antioxidants
(pharmacology)
- Glucose
|